Refine
Has Fulltext
- yes (331)
Is part of the Bibliography
- yes (331)
Year of publication
Document Type
- Journal article (331) (remove)
Language
- English (331) (remove)
Keywords
- multiple myeloma (33)
- cancer (10)
- Aspergillus (9)
- T cells (9)
- immunotherapy (9)
- inflammation (9)
- Aspergillus fumigatus (7)
- COVID-19 (7)
- apoptosis (7)
- cytokines (7)
- theranostics (7)
- CXCR4 (6)
- PET (6)
- B cells (5)
- NAFLD (5)
- deep learning (5)
- dendritic cells (5)
- neuroendocrine tumor (5)
- HIV (4)
- Medizin (4)
- Multiple myeloma (4)
- NASH (4)
- PRRT (4)
- Positronen-Emissions-Tomografie (4)
- SARS-CoV-2 (4)
- allogeneic stem cell transplantation (4)
- endoscopy (4)
- fungal infection (4)
- galactomannan (4)
- infection (4)
- machine learning (4)
- medicine (4)
- refractory (4)
- relapse (4)
- stem-cell transplantation (4)
- survival (4)
- therapy (4)
- Candida albicans (3)
- NK cells (3)
- PET/CT (3)
- Survival (3)
- T cell (3)
- T-cells (3)
- adalimumab (3)
- amyloidosis (3)
- aspergillosis (3)
- automation (3)
- biomarker (3)
- cell death (3)
- cell staining (3)
- colonoscopy (3)
- echocardiography (3)
- fatty liver disease (3)
- gastroenterology (3)
- giant cell arteritis (3)
- immune cells (3)
- immune response (3)
- immunosuppression (3)
- innate immunity (3)
- invasive aspergillosis (3)
- invasive pulmonary aspergillosis (3)
- lenalidomide (3)
- plasma cells (3)
- prognosis (3)
- prostate cancer (3)
- quality of life (3)
- regression analysis (3)
- rheumatoid arthritis (3)
- scleroderma (3)
- stem cell transplantation (3)
- systemic sclerosis (3)
- toxicity (3)
- 18F-FDG PET/CT (2)
- 3D printing (2)
- AIDS (2)
- AML (2)
- Activation (2)
- Acute myeloid leukemia (2)
- Allogeneic stem cell transplantation (2)
- Autologous hematopoietic stem cell transplantation (2)
- B cell (2)
- BRAF mutation (2)
- Bone marrow transplantation (2)
- Bone-marrow-transplantation (2)
- C-X-C motif chemokine receptor 4 (2)
- CA19-9 (2)
- CADe (2)
- CAR T cell (2)
- CAR T cells (2)
- CCL4 (2)
- CMV (2)
- FDG (2)
- FIB-4 (2)
- FcγR (2)
- GVHD (2)
- German Hepatitis C-Registry (2)
- GvHD (2)
- HBV (2)
- Imatinib (2)
- PD-L1 (2)
- RADS (2)
- Rectal cancer (2)
- Rituximab (2)
- Ruxolitinib (2)
- SSTR (2)
- Surgery (2)
- Systemic sclerosis (2)
- TNF (2)
- TNF receptor superfamily (2)
- Th17 (2)
- Tumor-necrosis-factor (2)
- [68Ga]PentixaFor (2)
- activation (2)
- acute myeloid leukemia (2)
- adaptive immunity (2)
- adverse events (2)
- alloreactive T cells (2)
- amplicon sequencing (2)
- anastomotic leakage (2)
- antirheumatic agents (2)
- anxiety (2)
- artificial intelligence (2)
- aspergillus fumigatus (2)
- autologous stem cell transplantation (2)
- beta-D-glucan (2)
- biomarkers (2)
- bone marrow immune-microenvironment (2)
- bortezomib (2)
- cancer immunotherapy (2)
- cancer microenvironment (2)
- cancer stem cells (2)
- chemokines (2)
- chemotherapy (2)
- chimeric antigen receptor (2)
- cholestasis (2)
- chronic hepatitis C (2)
- chronic kidney disease (2)
- chronic myelogenous leukemia (2)
- corticosteroids (2)
- cytotoxic T cells (2)
- daratumumab (2)
- deformation (2)
- depression (2)
- ejection fraction (2)
- endoluminal (2)
- endoradiotherapy (2)
- endothelial cells (2)
- extramedullary disease (2)
- fatigue (2)
- fibrosis (2)
- fungal infections (2)
- gemcitabine (2)
- gene (2)
- gene expression (2)
- gene regulation (2)
- graft versus host disease (2)
- hematologic malignancies (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- high risk (2)
- ileocecal resection (2)
- immunoassay (2)
- infectious diseases (2)
- invasive fungal infections (2)
- leukemia (2)
- lymphoma (2)
- management (2)
- memory B cells (2)
- metabolism (2)
- molecular imaging (2)
- mortality (2)
- mouse models (2)
- murine model (2)
- myeloma (2)
- nab-paclitaxel (2)
- negative pressure (2)
- obesity (2)
- object detection (2)
- oncology (2)
- organoids (2)
- oxidative stress (2)
- pancreatic cancer (2)
- peptide receptor radionuclide therapy (2)
- phosphorylation (2)
- platelets (2)
- polymyalgia rheumatica (2)
- pomalidomide (2)
- real world evidence (2)
- real-time PCR (2)
- regulatory T cells (2)
- resistance (2)
- risk stratification (2)
- sofosbuvir (2)
- spleen (2)
- surgical therapy (2)
- therapeutic drug monitoring (2)
- transplantation (2)
- treatment outcome (2)
- tumour immunology (2)
- vacuum-assisted closure (2)
- 11C-Methionine PET/CT (1)
- 177Lu (1)
- 18FDG-PET/CT (1)
- 2,5-diketopiperazines (1)
- 25-hydroxycholesterol 7 alpha-hydroxylase (1)
- 3D culture (1)
- 5-Fluorouracil (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-Pentixafor PET/CT (1)
- ABCG2 (1)
- ABL gene (1)
- AKT-signaling (1)
- ALiOS (1)
- AMPK (1)
- APRI (1)
- ARONJ (1)
- ASE formula (1)
- ATPase activity (1)
- ATTRv amyloidosis (1)
- Active disease (1)
- Acute lymphoblastic leukemia (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (AML) (1)
- Adaptive cell transfer (1)
- Akt (1)
- Allogeneic transplantation (1)
- Alpelisib (1)
- Alpha therapy (1)
- Alpha-dependent apoptosis (1)
- Amphibia (1)
- Antibodies (1)
- Apoptosis (1)
- Arthroleptis amphibia (1)
- Ascaris lumbricoides (1)
- Aspergillus sp. (1)
- Autoimmune diseases (1)
- B cell culture (1)
- B cell receptors (1)
- B-cell lymphoma (1)
- B-cells (1)
- BAL (1)
- BCOR (1)
- BCORL1 (1)
- BH3-only proteins (1)
- BON-1 (1)
- Bacteria (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Biomarker (1)
- Blood (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Breath tests (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- C-IAP1 (1)
- C1q/TNF related protein (CTRP) (1)
- C57BL/KALWRIJ mouse (1)
- CAPA (1)
- CAR T (1)
- CAR T-cell (1)
- CAR-T-cell (1)
- CASPASE-3 (1)
- CCL3 (1)
- CCL5 (1)
- CCN1 (1)
- CCS (1)
- CD11b+ myeloid cells (1)
- CD20 (1)
- CD274 (1)
- CD319 (1)
- CD38 (1)
- CD4(+) (1)
- CD4(+) T-cells (1)
- CD40L (1)
- CD95 (1)
- CIAP1 (1)
- CML (1)
- CMR (1)
- CMV reactivation (1)
- CMV-specific cellular immunity (1)
- CNS cancer (1)
- COX2 expression (1)
- CP-690,550 (1)
- CRISPR/Cas9 (1)
- CS1 (1)
- CXCL10 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer treatment (1)
- Candida sp. (1)
- Capicua transcriptional repressor (1)
- Caspase-8 activation (1)
- Central nervous system (1)
- Central nervous system infection (1)
- Chronic lymphoblastic leukemia (1)
- Chronic myeloid leukaemia (1)
- Chronic myeloid leukemia (1)
- Clinical practice guidelines (1)
- Clinical remission (1)
- Complex (1)
- Conditioning regimen (1)
- Copy number changes (1)
- Coronavirus Disease 2019 (1)
- Crohn’s Disease (1)
- Crohn’s disease (1)
- Cytokine receptors (1)
- D insufficiency (1)
- D serum-levels (1)
- DAS28 (1)
- DExD/H-Box RNA helicase (1)
- DMARD (1)
- DNA damage (1)
- DOTATOC (1)
- Dara-KDT-P(A)CE (1)
- Dendritische Zelle (1)
- Diagnosis (1)
- Donor lymphocytes (1)
- Dopamine (1)
- Drug development (1)
- Drug metabolism (1)
- Drug resistance (1)
- Drug-free remission (1)
- Duchenne muscular dystrophy (1)
- EAE (1)
- EGFR (1)
- Elderly (1)
- EndoVAC and small bowel (1)
- Enzyme Regulation (1)
- EpCAM (1)
- Epstein-Barr virus-induced gene 2 (1)
- European experience (1)
- European experts (1)
- European group (1)
- Expression (1)
- Extramedullary disease (1)
- FDG-PET/CT (1)
- FOLFIRI (1)
- FOLFOX (1)
- Factor receptor (1)
- Fak regulation (1)
- Fludarabine (1)
- Fludarabine-treosulfan (FT) (1)
- Fn14 (1)
- Fungal (1)
- Fusarium (1)
- GCA (1)
- GI (1)
- GLP-1 (1)
- GRAID (1)
- GUT-directed hypnotherapy (1)
- GVL (1)
- Gastrointestinal (1)
- Gaussia princeps luciferase (GpL) (1)
- Genetics research (1)
- Glucose metabolism (1)
- Glutamate-induced excitotoxicity (1)
- Graft versus Tumor (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- Grave’s disease (1)
- Gruppo-italiano (1)
- Guideline (1)
- Guinea pig model (1)
- Guinean rain forest (1)
- HAQ (1)
- HB-EGF (1)
- HCV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HD (1)
- HECT Ligase (1)
- HEV (1)
- HGF (1)
- HIV infections (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- HLA antigens (1)
- HLA-E matching (1)
- HNSCC (1)
- HSC (1)
- HSTC outcome (1)
- HT29 cells (1)
- HUWE1 (1)
- Haematology (1)
- Haploidentical (1)
- Hematopoietic stem cell transplantation (1)
- Hepatitis B virus (1)
- Hepatitis B virus reactivation (1)
- Hepatitis C (1)
- Hepatitis C infection (1)
- Hepatitis E (1)
- Herpes simplex encephalitis (1)
- Herpes simplex virus (1)
- Hippo signaling (1)
- Hsp90 (1)
- Human immunodefiency virus (1)
- IDO-1 (1)
- IFN-gamma (1)
- IFN-γ ELISpot (1)
- IFNG (1)
- IL-12 family (1)
- IL28B (1)
- IL28B polymorphisms (1)
- IRF4 (1)
- Immune receptor signaling (1)
- Immunocompromised patient (1)
- Immunology (1)
- Improved survival (1)
- Induced apoptosis (1)
- Infections (1)
- Infectious Diseases (1)
- Infectious complications (1)
- Infectious disease (1)
- Inflammation (1)
- Influenzae type B (1)
- Interleukin-10 (1)
- Interleukin-2 (1)
- Interleukin-5 (1)
- Intracellular domain (1)
- Invasive Aspergillosis (1)
- Invasive fungal-infections (1)
- JAK2 (1)
- JCV (1)
- Jak kinases (1)
- KRAS (1)
- Kappa-B activation (1)
- Kappa-B pathway (1)
- Killer cell immunoglobulin-like receptors (1)
- Kono-S anastomosis (1)
- LATE DEATHS (1)
- LEOSS (1)
- LINE-1 retrotransposition (1)
- LPS (1)
- Late mortality (1)
- Li-Fraumeni syndrome (1)
- Lichtheimia (1)
- Ligand (1)
- Lipid metabolism (1)
- Liposomal amphotericin-B (1)
- Liver cirrhosis (1)
- Low-dose acyclovir (1)
- Lymphomas (1)
- M30 (1)
- MAG3 (1)
- MAPKAPK2 (1)
- MASLD (1)
- MCL-1 (1)
- MEDAS (1)
- MEK/ERK-signaling (1)
- MHC molecules (1)
- MIP-1β (1)
- MOPC315.BM (1)
- MOR202 (1)
- MPACT (1)
- MS-18 (1)
- MTB (1)
- MTX (1)
- MUD (1)
- MUST-Score (1)
- MYC (1)
- Malignant melanoma (1)
- Mechanisms (1)
- Medicine (1)
- Melanoma (1)
- Memory B cells (1)
- Mesenchymal stem cells (1)
- Met (1)
- Methotrexate (1)
- Midollo-Osseo (1)
- Migration (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Molecular Biophysics (1)
- Molecularly targeted therapy (1)
- Multiple (1)
- Multiple Myeloma (1)
- Multivariate analysis (1)
- Mycobacterium avium (1)
- Myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- NA (1)
- NADPH oxidase (1)
- NET (1)
- NF-Kappa-B (1)
- NF-κB/NFAT reporter cells (1)
- NFAT (1)
- NFATc1 (1)
- NFkB (1)
- NFkB-relatedgenes (1)
- NFκB (1)
- NGS (1)
- NK-cells (1)
- NLRP3 (1)
- NRF2 (1)
- Necrosis (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- OSM (1)
- Oldenburg burnout inventory (1)
- Oncology (1)
- P14ARF (1)
- P67(PHOX) (1)
- PCR (1)
- PHQ-9 (1)
- PML (1)
- PMR (1)
- POU6F2-AS2 (1)
- PRO (1)
- PROM’s (1)
- PSMC2 (1)
- PU.1 (1)
- Parkinson's disease (1)
- Parkinsons-disease (1)
- Pathogenesis (1)
- Petropedetidae (1)
- Phase- (1)
- Phrynobatrachus amphibia (1)
- Pneumocystis-carinii-pneumonia (1)
- Polymerase chain raction (1)
- Pom‐PAD‐Dara (1)
- Positron emission tomography (1)
- Prediction (1)
- Prodigy (1)
- Prognostic scoring system (1)
- Progressive multifocal leukoencephalopathy (1)
- Pseudomonas aeruginosa (1)
- QGP-1 (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- R-CHOP (1)
- RIG-I (1)
- RIP1 (1)
- RNA (1)
- RNA extraction (1)
- ROR1 (1)
- RT-qPCR (1)
- RYGB (1)
- Radiochemotherapy (1)
- Radionuclide Therapy (1)
- Radiotherapy (1)
- Ranidae (1)
- Real-time PCR (1)
- Regulatory-cells (1)
- Respiratory syncytial virus (1)
- Responses (1)
- Rheumatoid Arthritis (1)
- Rheumatoid arthritis (1)
- Rhizopus (1)
- Rhizopus arrhizus (1)
- Risk factors (1)
- S100A8/S100A9 (1)
- SF-12 (1)
- SF-36 (1)
- SGLT2 inhibitors (1)
- SLAMF7 (1)
- STAT1 (1)
- STAT3 activation (1)
- STS (1)
- SVR (1)
- Saccharomyces cerevisiae (1)
- ScFv (1)
- Scleroderma (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Sibling donor (MSD) (1)
- Signal transduction (1)
- Signaling complex (1)
- Single-chain TNF (1)
- Sjögren’s syndrome (1)
- Skin cancer screening (1)
- Societe Francaise (1)
- Spleen (1)
- Splicing (1)
- Stage distribution (1)
- Standardisierung (1)
- Stem cell transplantation (1)
- Stimulating factor (1)
- Stromal cells (1)
- Structural Biology (1)
- Suppression (1)
- Survival analysis (1)
- Synovitis (1)
- T-Track\(^®\) TB (1)
- T-cell transfer (1)
- TB (1)
- TLR agonists (1)
- TME (1)
- TNF receptor associated factor 2 (TRAF2) (1)
- TNF-related apoptosis-inducing ligand (1)
- TNFR2 (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TNM staging (1)
- TP53 (1)
- TRAF2 (1)
- TRAIL (1)
- TSLP (1)
- TTR knockdown (1)
- TTR stabilization (1)
- TWEAK (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Th17 cells (1)
- Th9 (1)
- Therapy (1)
- Thiotepa-busulfan-fludarabine (TBF) (1)
- Time interval (1)
- Translational research (1)
- Transport (1)
- Treatment (1)
- Tregs (1)
- Trypanosoma (1)
- Tyrosine phosphorylation (1)
- Ubiquitin (1)
- Unrelated donor (UD) (1)
- Upper Guinea (1)
- VAS (1)
- VCE (1)
- VLA-1 (1)
- Validation (1)
- Varicella-Zoster-Virus (1)
- Varicella-zoster-virus (1)
- Viral (1)
- Waldeyer’s tonsillar ring (1)
- Western diet (1)
- Wnt (1)
- X-Ray Chrystallography (1)
- YAP (1)
- ZIP (1)
- Zelllysat (1)
- Zytokin-induzierte Killerzellen (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-methionine (1)
- abnormalities (1)
- acoustic radiation force impulse imaging (1)
- actin (1)
- activating receptors (1)
- active TB (1)
- active antiretroviral therapy (1)
- acute Graft versus Host Disease (1)
- acute graft-versus host disease (1)
- acute graft-versus-host disease (1)
- acute hypobaric hypoxia (1)
- acute kidney injury (1)
- acute leukemia (1)
- acute leukemia (AL) (1)
- acute lymphoblastic leukaemia (1)
- acute lymphoblastic leukemia (1)
- acute myelogenous leukemia (1)
- acute myeloid leukaemia (1)
- acute myeloid-leukemia (1)
- acute respiratory distress syndrome (1)
- adenocarcinoma of the ampulla of Vater (1)
- adhesion molecule (1)
- adiponectin (1)
- adjuvant (1)
- adoptive cell therapy (1)
- adoptive transfer (1)
- adrenocortical carcinoma (1)
- adults (1)
- afatinib (1)
- affinity (1)
- africans (1)
- agar diffusion test (1)
- agonism (1)
- agonist (1)
- agonistic antibodies (1)
- all-cause mortality (1)
- alloSCT patients (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alternative to animal testing (1)
- alveolar epithelium (1)
- amphotericin B (1)
- amsacrine (1)
- amyloid‐directed antibodies (1)
- amyotrophic lateral sclerosis (1)
- anaplastic medulloblastoma (1)
- anastomotic leak (1)
- androgen deprivation therapy (1)
- anemia (1)
- animal model (1)
- annotation (1)
- anti-infective vaccination (1)
- anti-proliferative effects (1)
- antibody (1)
- anticoagulation (1)
- antifungal (1)
- antifungal agents (1)
- antifungals (1)
- antigen loss (1)
- antigen processing and presentation (1)
- antigen-presenting cells (1)
- antigens (1)
- antimicrobial responses (1)
- antimicrobials (1)
- antiphospholipid syndrome (1)
- antiresorptive drug-related osteonecrosis of the jaw (1)
- antiretroviral therapy (1)
- antithrombotic therapy (1)
- antiviral treatment (1)
- aplastic anemia (1)
- april (1)
- arthritis (1)
- at-home sampling (1)
- atrial fibrillation (1)
- autoantibodies (1)
- autoimmune disease (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous hematopoietic stem cell transplantation (1)
- autologous transplantation (1)
- autologous tumor (1)
- autophagy (1)
- axi-cel (1)
- axonal transcriptome (1)
- bacterial infection (1)
- beta-oxidation (1)
- bile (1)
- biliary-tract cancer (1)
- binding (1)
- biodiversity (1)
- biodiversity hotspot (1)
- biofilm formation (1)
- biological fluorescence (1)
- biomarkers Myelomas (1)
- biophosphonate (1)
- biophysics (1)
- biopsy (1)
- biosynthesis (1)
- bispecific antobodies (1)
- blast cell lysate (1)
- blast-derived RNA (1)
- blinatumomab (1)
- blinatumoman (1)
- blood (1)
- blood flow (1)
- bone (1)
- bone adaptation (1)
- bone disease (1)
- bone imaging (1)
- bone marrow (1)
- bone marrow angiogenesis (1)
- bone marrow cells (1)
- bone marrow failure (1)
- bone marrow homing (1)
- bone marrow transplantation (1)
- bone remineralization (1)
- bone-disease (1)
- bone-mineral density (1)
- bortezomib plus dxamethasone (1)
- brain tumor (1)
- breakpoint (1)
- breakthrough infection (1)
- breast cancer (1)
- bridge-to-transplant (1)
- bridging (1)
- bronchoalveolar lavage fluid (1)
- burnout (1)
- c-reactive protein (1)
- calcium imaging (1)
- calcofluor white staining (1)
- calprotectin (1)
- cancer care (1)
- cancer immune cell therapy (1)
- cancer metabolism (1)
- cancer of unknown primary (CUP) (1)
- cancer predisposition (1)
- cancer prevention (1)
- cancer treatment (1)
- cancer vaccines (1)
- cancer-induced bone disease (1)
- capture (1)
- carcinoma (1)
- carcinoma cells (1)
- cardiac thrombi (1)
- cardiac transplantation (1)
- care (1)
- carfilzomib (1)
- caspase activation (1)
- caspase-3 (1)
- ceftriaxone (1)
- cell binding (1)
- cell cycle (1)
- cell of origin (1)
- cell therapy and immunotherapy (1)
- cell viability testing (1)
- cell wall (1)
- cellular inhibitor of apoptosis 1/2 (cIAP1/2) (1)
- cereblon expression (1)
- cerebral aspergillosis (1)
- cerebrospinal fluid (1)
- cfRNA (1)
- chemistry (1)
- chemokine receptor (1)
- chenodeoxycholate (1)
- chewed (1)
- children (1)
- cholesterol 25 hydroxylase (1)
- chronic Hepatitis C (1)
- chronic distress (1)
- chronic heart failure (1)
- chronic myeloid leukemia (1)
- chronic phase (1)
- cicatricial pemphigoid (1)
- circulating micrornas (1)
- cirrhosis (1)
- class-I (1)
- clinical imaging (1)
- clinical trial (1)
- clinical-practice (1)
- cluster analysis (1)
- coagulation (1)
- cognitive hypnotherapy (1)
- cognitive impairment (1)
- collagens (1)
- colorectal cancer (1)
- combination testing (1)
- combination therapy (1)
- commensal bacteria (1)
- common genetic determinants (1)
- common variable immunodeficiency (1)
- common variable immunodeficiency (CVID) (1)
- comorbidities (1)
- comparability (1)
- comparison (1)
- complement system (1)
- complication (1)
- complications (1)
- comprehensive management (1)
- comprehensive psychosomatic assessment (1)
- computed tomography (1)
- consensus statement (1)
- conservation (1)
- contrast-enhanced ultrasound. (1)
- corticosteroids and cyclophosphamide (1)
- critically ill patients (1)
- cyclophosphamide (FLAMSA) (1)
- cytarabine dose (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytogenetic response (1)
- cytogenetics (1)
- cytokine (1)
- cytokine production (1)
- cytokine-induced killer cells (1)
- cytokinesis (1)
- cytopenia (1)
- cytotoxicity (1)
- cytotoxicity receptors (1)
- dabrafenib (1)
- daratumumab monotherapy (1)
- ddPCR (1)
- death rates (1)
- deep metric learning (1)
- definition (1)
- degradation (1)
- deletion 17P (1)
- dendritische Zellen (1)
- denritic cells (1)
- derivates (1)
- detoxification (1)
- dexamethasone (1)
- diagnostic medicine (1)
- diagnostics (1)
- different imatinib dose regimens (1)
- differentiated thyroid tumor (1)
- differentiation (1)
- diffuse large B-cell lymphoma (1)
- diffusion weighted mri (1)
- diketopiperazines (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- discharge definition (1)
- discordance (1)
- disease (1)
- disease comorbidities (1)
- disease score (1)
- disease severity (1)
- disease-activity score (1)
- disengagement (1)
- disorder of immunity (1)
- disorders (1)
- dolutegravir (1)
- donor-cell leukemia (1)
- downstream (1)
- drug (1)
- drug adherence (1)
- drug monitoring (1)
- drug resistance (1)
- drug screening (1)
- drug-induced immune hemolytic anemia (1)
- drug–drug interactions (DDIs) (1)
- duodenal perforation (1)
- duodenal trauma (1)
- early applied higher imatinib dosages (1)
- early detection (1)
- early onset sepsis (1)
- elderly (1)
- elderly patients (1)
- elderly persons (1)
- electrogastrographic egg activities (1)
- elotuzumab (1)
- emtricitabine (1)
- enal impairment (1)
- endoscopic (1)
- endoscopic full thickness resection (eFTR) (1)
- endoscopic instruments (1)
- endoscopic intervention (1)
- endosponge (1)
- engaging aantibody (1)
- engraftment syndrome (1)
- enzyme-linked immunoassays (1)
- epidemiology (1)
- epidemology (1)
- epithelial-mesenchymal transition (1)
- erythropoiesis-stimulating agents (1)
- esophageal perforation (1)
- european leukemia net (1)
- exhaustion (1)
- expression (1)
- extramedullary (1)
- extramedullary hematopoiesis (1)
- familial amyloid polyneuropathy (FAP) (1)
- fatty liver (1)
- fear of progression (1)
- fever (1)
- few-shot learning (1)
- fibrin D-dimer (1)
- fibroblast activation protein (1)
- fibrosis progression (1)
- fibrotest (1)
- fine-needle-aspiration (1)
- fluorescence (1)
- fluorescence imaging (1)
- fluorescence in situ hybridization (FISH) (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- folinic acid (1)
- free survival (1)
- full-thickness resection device (FTRD) (1)
- functional abdominal pain (1)
- fungal aerosolization (1)
- fungal disease (1)
- fungal host response (1)
- fungal infection model (1)
- fungal molecular diagnostics (1)
- fungal sinusitis (1)
- fungi (1)
- gRNA-only (1)
- galectin-2 (1)
- gammadelta T cells (1)
- gastric bypass (1)
- gastric cancer (1)
- gastric emptying (1)
- gastrointestinal dysfunction (1)
- gastrointestinal infections (1)
- gastrointestinal perforation (1)
- gastrointestinal symptoms (1)
- gastrointestinal tract (1)
- gene expression data (1)
- gene regulation in immune cells (1)
- gene therapy (1)
- gene-environment interaction (1)
- genetic polymorphisms (1)
- genetic susceptibility (1)
- genital warts (1)
- genus (1)
- german people (1)
- glecaprevir/pibrentasvir (1)
- glial fibrillary acidic protein (1)
- glioblastoma (1)
- graft-versus-host-disease (1)
- granulocytes (1)
- group 3 (1)
- group consensus statement (1)
- growth differentiation factor 15 (1)
- growth-factor receptor 3 (1)
- growth-factor-receptor (1)
- gut–liver axis (1)
- haematopoietic stem cell (1)
- haploidentical γδ T lymphocytes (1)
- head and neck cancer (1)
- health care (1)
- health-assessment questionnaire (1)
- healthy volunteers (1)
- heart failure (1)
- helicase (1)
- helicobacter pylori infection (1)
- hematological malignancies (1)
- hematology (1)
- hematopoietic (1)
- hematopoietic SCT (1)
- hematopoietic cell transplantation (1)
- hematopoietic stem cell transplantation (HSCT) (1)
- hematopoietic stem cells (1)
- hemodialysis (1)
- hemolysis (1)
- hemolytic anemia (1)
- hepatic stellate cells (1)
- hepatitis B virus (1)
- hepatocellular carcinoma (1)
- high-risk cytogenetics (1)
- high-risk hematology (1)
- highly-active antiretroviral therapy (1)
- homing (1)
- hospitalization (1)
- host defense (1)
- host genetics (1)
- host response (1)
- human biomarker (1)
- human cholangiocellular carcinoma (1)
- human cytomegalovirus (HCMV) (1)
- human dendritic cells (1)
- human hepatic cells (1)
- human intrahepatic cholangiocarcinoma (1)
- human leukocyte antigen-E (HLA-E) (1)
- human multiple-myeloma (1)
- human papillomavirus (1)
- human pathogen (1)
- human pathogenic fungi (1)
- humans (1)
- hybrid messenger RNA (1)
- hydroxy-dabrafenib (1)
- hypersensitivity (1)
- hypnotic susceptibility (1)
- hypogammaglobulinemia (1)
- i-131 uptake (1)
- idiotype (1)
- image classification (1)
- imaging the immune system (1)
- immune activation (1)
- immune cell recruitment (1)
- immune control (1)
- immune impairment (1)
- immune modulation (1)
- immune monitoring (1)
- immune receptors (1)
- immune reconstitution (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunocompromised patients (1)
- immunogenetics (1)
- immunoglobulin rearrangement (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- immunology (1)
- immunophenotyping (1)
- immunosurveillance (1)
- immunotherapeutics (1)
- in vitro model (1)
- in vivo cell expansion (1)
- inborn errors of immunity (IEIs) (1)
- incidence (1)
- independent marker (1)
- individual mind state (1)
- individualized surgery (1)
- induce cyclooxygenase-2 expression (1)
- induced apoptosis (1)
- induction regimen (1)
- infection detection (1)
- inflammasome (1)
- inflammation marker (1)
- inflammation-induced tissue demage (1)
- infusion (1)
- inhibition (1)
- inhibitor (1)
- inhibitory receptors (1)
- injury (1)
- innate immune response (1)
- instrument (1)
- insulin (1)
- insulin signaling (1)
- integrase inhibitor (1)
- integrins (1)
- intensity of attention (1)
- interaction (1)
- interacts (1)
- interferon (1)
- interferon alpha (1)
- interferon alpha (IFNα) (1)
- interferon alpha signalling (1)
- interferon gamma (1)
- interferon-alpha (1)
- interferon-free (1)
- intergroupe francophone (1)
- interleukin 1 (1)
- interleukin 18 (1)
- interleukin-6 (1)
- interleukin-9 (1)
- intermediate dose Ara-C (1)
- intervention (1)
- intestinal-type adenocarcinoma (1)
- intestine (1)
- intramolecular Michael addition (1)
- intratumoral microbiota (1)
- invasive candidiasis (1)
- invasive fungal infection (1)
- iohexol (1)
- irinotecan (1)
- iron homeostasis (1)
- irritable-bowle-sondrome (1)
- ischemic stroke (1)
- isoforms (1)
- ivory coast (1)
- janus kinase inhibitor (1)
- keratin-18 (1)
- kidney (1)
- kidney cancer (1)
- kidney function (1)
- kinase inhibitors (1)
- kinease (1)
- kinesin (1)
- laminin 332 (1)
- large B-cell lymphoma (1)
- lasso regression (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide-refractory patients (1)
- lentiviral transduction (1)
- lesions (1)
- library screening (1)
- life-threatening side-effects (1)
- lifestyle habits (1)
- ligand incompatibility (1)
- ligand trail (1)
- lineage (1)
- liquid biopsy (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liraglutide (1)
- liver (1)
- liver diseases (1)
- liver fibrosis (1)
- locally advanced disease (1)
- loss-of-function (1)
- low molecular heparin (1)
- lymph node metastases (1)
- lymph node stromal cells (1)
- lymph node transplantation (1)
- lymphocyte activation (1)
- lymphocytes (1)
- lysine biosynthesis (1)
- mAb engineering (1)
- mRNA (1)
- mRNA-Seq (1)
- mTOR (1)
- magnetic resonance imaging (1)
- malignant transformation (1)
- malnutrition (1)
- mammalian genomics (1)
- mantle cell lymphoma (1)
- marrow plasma cells (1)
- matrix metallopeptidase-1 (1)
- mebendazole (1)
- mechanical loading (1)
- mechanism (1)
- mechanosensing (1)
- mechanotransduction (1)
- megakaryocytes (1)
- melanoma (1)
- melanoma malignancy (1)
- melanoma therapy (1)
- mental impairment (1)
- mesenteric lymph node (1)
- messenger RNA (1)
- metabolic tumor volume (MTV) (1)
- metastasis (1)
- metastasis-directed therapy (1)
- methionine (1)
- methotrexate (1)
- methylation (1)
- miR-122 (1)
- microbiome (1)
- microbiota-derived metabolites (1)
- micronuclei (1)
- microswimmer (1)
- mindfulness (1)
- minimal residual disease (1)
- minimally important difference (1)
- minimally invasive surgery (1)
- mismatch (1)
- missing self (1)
- mitochondrial DNA (1)
- mixed infection (1)
- modified Rodnan skin score (mRSS) (1)
- mold disease (1)
- mold exposure (1)
- molecular data (1)
- molecular diagnosis (1)
- molecular response in cml (1)
- monoclonal antibody (1)
- monoclonal gammopathy (1)
- monoclonal-antibodies (1)
- monocytes (1)
- motivational level (1)
- mouse feeding model (1)
- mouse model (1)
- mouse models DNA damage (1)
- mtDNA (1)
- mucormycosis (1)
- mucous membrane pemphigoid (1)
- multicomponent Ugi-type reaction (1)
- multimodal (1)
- multiparameter flow-cytometry (1)
- multiparameter flow-cytpmetry (1)
- multiparametric flow cytometry (1)
- multiple myeloma Lesions (1)
- multiplex PCR (1)
- multiplicity of infection (1)
- muscle (1)
- music (1)
- mutation (1)
- mycophenolate (1)
- mycophenolic acid (1)
- mycoses (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- myeloma cells (1)
- myofibroblast (1)
- myokines (1)
- nOAC (1)
- naive T-cell gene editing (1)
- nanoparticle albumin-bound paclitaxel (1)
- natural killer cell (1)
- natural killer cells (1)
- natural language processing (1)
- naïve B cells (1)
- necroptosis (1)
- necrotic cell death (1)
- neoadjuvant (1)
- neoadjuvant chemotherapy (1)
- network (1)
- neuralgic amyotrophy (1)
- neuroendocrine tumor (NET) (1)
- neuroimmunology (1)
- neurology (1)
- neutropenic fever (1)
- new species (1)
- newly diagnosed (1)
- newly-diagnosed myeloma (1)
- nicotinamide (1)
- no correlation (1)
- nomogram (1)
- non-interventional (1)
- non-invasive fibrosis assessment (1)
- nonalcoholic fatty liver disease (1)
- none (1)
- normal values (1)
- novel therapies (1)
- nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NFκB) (1)
- nuclear receptors (1)
- nucleoside transporter (1)
- nucleotide excision repair (1)
- nutritional counseling (1)
- nutritional medical needs (1)
- nutritional risk screening (1)
- obinutuzumab (1)
- observational (1)
- oesophagogastroduodenoscopy (1)
- older patients (1)
- oligmometastases (1)
- oligorecurrence (1)
- oncobiome (1)
- oncologist (1)
- oncology outpatients (1)
- oncostatin M (1)
- ontology (1)
- operating platform (1)
- ophthalmic artery (1)
- optic nerve (1)
- oral anticancer drugs (1)
- oral anticoagulants (1)
- oral microbiome (1)
- orbit (1)
- orthotopic xenograft (1)
- osimertinib (1)
- osteokines adaptation (1)
- osteonecrosis of the jaw (1)
- osteoradionecrosis (1)
- outbreak (1)
- outcomes research (1)
- outreach (1)
- overdose (1)
- oxaliplatin (1)
- p53 (1)
- paediatric cancer (1)
- pan-RCC (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic head cancer (1)
- pancreatic neoplasms (1)
- pancreatobiliary type (1)
- panobinostat (1)
- participation in clinical trials (1)
- pathogen-associated molecular patterns (1)
- pathogenic TP53 germline variant (1)
- pathophysiology (1)
- pathway (1)
- patient access (1)
- patient-reported outcomes (1)
- patients with multiple myeloma (1)
- pattern (1)
- pattern recognition receptors (1)
- pediatric (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- peptide (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) (1)
- personalised medicine (1)
- personalized medicine (1)
- pharmacokinetic (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- pharmacology (1)
- phosphatidyl-inositol-3-kinase p110 alpha (1)
- phosphatidylinositol 3-kinase/Akt (1)
- physical activity (1)
- physicians (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- plasma cell disorder (1)
- plasma clearance (1)
- platelet activation (1)
- platelet aggregation (1)
- plus dexamethasone (1)
- point shear wave elastography (1)
- poly(ADP-ribose) polymerase inhibitors (1)
- polymerase-chain-reaktion (1)
- polyp (1)
- population pharmacokinetics (1)
- population-based cohort (1)
- porcine large animal model (1)
- posaconazole (1)
- positron emission tomography (1)
- positron emission tomography/computed tomography (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- precision medicine (1)
- precision oncology (1)
- prediction (1)
- predictive factor (1)
- prenatal paternal depression (1)
- preoperative planning (1)
- prevalence (1)
- primary biliary cholangitis (1)
- primary immunodeficiencies (1)
- primary immunodeficiency (1)
- primary sclerosing cholangitis (1)
- probe-based real-time PCR (1)
- progression (1)
- prolonged cytopenia (1)
- prophylaxis (1)
- prospective (1)
- prospective feasibility (1)
- prostaglandin E2 (1)
- prostate-specific membrane antigen (PSMA) (1)
- proteasome inhibitors (1)
- psoriasis (1)
- psychology (1)
- psychosocial (1)
- public health (1)
- pulmonary aspergillosis (1)
- pulmonary immune response (1)
- radiation therapy (1)
- radiogenomics (1)
- radioligand therapy (1)
- radionuclide therapy (1)
- rainforest (1)
- raltegravir (1)
- randomized controlled trial (1)
- randomized phase-3 trial (1)
- rapid prototyping (1)
- rare SNP (1)
- real life setting (1)
- real time PCR (1)
- real world data (1)
- real-time (1)
- recall antigen (1)
- receptor expression (1)
- receptor tyrosine kinases (1)
- recognition (1)
- recombinant-human-erythropoietin (1)
- rectal sensitivity (1)
- rectum (1)
- recurrent Tako-Tsubo cardiomyopathy (1)
- reference data (1)
- region (1)
- relapsed (1)
- relapsed and refractory (1)
- relaxation (1)
- renal failure (1)
- renal function (1)
- renal perfusion (1)
- renal scintigraphy (1)
- reported outcomes (1)
- reporting and data systems (1)
- respiratory virus (1)
- resting NK cells (1)
- rheumatoid (1)
- rheumatoid arhritis (1)
- ribavirin serum levels (1)
- risk factor (1)
- risk factors (1)
- risk pregnancy (1)
- risk factor analysis (1)
- rituximab (1)
- ruxolitinib (1)
- safety (1)
- salt consumption (1)
- salt-intake-related behavior (1)
- salvage (1)
- sarcoma (1)
- scid mice (1)
- screening for distress (1)
- second line therapy (1)
- secondary metabolite gene cluster (1)
- serotonin (1)
- serum biomarkers (1)
- serum creatinine (1)
- serum retention (1)
- severe fibrosis (1)
- signal inhibition (1)
- signal transduction (1)
- signaling (1)
- significance MGUS (1)
- silkworm (1)
- sirolimus (1)
- skeletal mechanobiology (1)
- skin equivalents (1)
- sleeping sickness (1)
- slice culture (1)
- small bowel bleeding (1)
- small interfering RNAs (1)
- smoldering multiple-myeloma (1)
- smoldering myeloma (1)
- somatic symptom burden (1)
- somatostatin receptor (1)
- somatostatin receptor (SSTR) (1)
- spatial heterogeneity (1)
- stable isotope breath tests (1)
- standardization (1)
- steatosis (1)
- steatotic liver disease (1)
- stereotactic body radiotherapy (1)
- stimulation (1)
- strategy (1)
- streptococci (1)
- stress (1)
- stress level (1)
- stromal cells (1)
- structural biology (1)
- subunit (1)
- suicide attempt (1)
- sulfur (1)
- super-resolution microscopy (1)
- superior (1)
- suppression (1)
- surgical care (1)
- surgical manipulator (1)
- susceptibility (1)
- sustained virological response (1)
- symptom burden (1)
- systemic candidiasis (1)
- systemic therapy (1)
- t-lymphocytes (1)
- target validation (1)
- targeted therapies (1)
- targeted therapy (1)
- targeting (1)
- taxonomy (1)
- tenofovir disaproxil fumarate (1)
- term-follow-up (1)
- thalidomide maintenance (1)
- thrombin (1)
- thromboembolism (1)
- thrombopoiesis (1)
- thrombosis (1)
- tissue engineering (1)
- tocilizumab (1)
- tocilizumab (IL-6 inhibitor) (1)
- total body irradiation/busulfan (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- trabectedin (1)
- trail-mediated apoptosis (1)
- trametinib (1)
- transactivation (1)
- transanal endoscopic microsurgery (TEM) (1)
- transcriptome (1)
- transcripts (1)
- transformer (1)
- transient elastography (1)
- transient regulatory T-cell targeting (1)
- translational research (1)
- translocation (1)
- transporter protein associated with antigen processing-1 (TAP1) (1)
- transstomal endoluminal vacuum therapy (1)
- transthyretin (1)
- treatment response (1)
- tsetse fly (1)
- tuberculosis (1)
- tumor burden (1)
- tumor microenvironment (1)
- tumor microenvironment (TME) (1)
- tumor necrosis factor (TNF) (1)
- tumor specific antigen (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumormicroenvironment (1)
- tumor‐specific antigen (1)
- tyrosine-kinase inhibitor (1)
- ulcerative colitis (1)
- undetermined significance MGUS (1)
- ursodeoxycholic acid (1)
- validation (1)
- vascularization (1)
- vasculature (1)
- vasculitis (1)
- venetoclax (1)
- venous thromboembolic disease (1)
- verteporfin (1)
- video capsule endoscopy (1)
- video object detection (1)
- viral clearance (1)
- viral infection (1)
- viral load (1)
- viral replication (1)
- virulence (1)
- virus (1)
- virus infection (1)
- virus-infected cells (1)
- virus-specific T-cell (1)
- vitamin D (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- warfarin interruption (1)
- water load test (1)
- weight gain (1)
- whole blood specimens (1)
- whole-body imaging (1)
- yoga (1)
- zinc (1)
- zoledonic acid (1)
- β-catenin (1)
- γδ T cells (1)
Institute
- Medizinische Klinik und Poliklinik II (331) (remove)
Sonstige beteiligte Institutionen
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (2)
- Johns Hopkins School of Medicine (2)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (1)
- Department of Hematology and Oncology, Sana Hospital Hof, Hof, Germany (1)
- Department of Laboratory Medicine and Medicine Huddinge, Karolinska Institutet and University Hospital, Stockholm, Sweden (1)
- Department of Medicine A, University Hospital of Münster, Münster, Germany (1)
- Interdisciplinary Center for Clinical Research (IZKF), Würzburg, Germany (1)
- Interdisziplinäres Amyloidosezentrum Nordbayern (1)
- Johns Hopkins University School of Medicine (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study
(2024)
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.
At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders — including patients suffering from cancer — were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.
Prevention of the effectiveness of anti-tumor immune responses is one of the canonical cancer hallmarks. The competition for crucial nutrients within the tumor microenvironment (TME) between cancer cells and immune cells creates a complex interplay characterized by metabolic deprivation. Extensive efforts have recently been made to understand better the dynamic interactions between cancer cells and surrounding immune cells. Paradoxically, both cancer cells and activated T cells are metabolically dependent on glycolysis, even in the presence of oxygen, a metabolic process known as the Warburg effect. The intestinal microbial community delivers various types of small molecules that can potentially augment the functional capabilities of the host immune system. Currently, several studies are trying to explore the complex functional relationship between the metabolites secreted by the human microbiome and anti-tumor immunity. Recently, it has been shown that a diverse array of commensal bacteria synthetizes bioactive molecules that enhance the efficacy of cancer immunotherapy, including immune checkpoint inhibitor (ICI) treatment and adoptive cell therapy with chimeric antigen receptor (CAR) T cells. In this review, we highlight the importance of commensal bacteria, particularly of the gut microbiota-derived metabolites that are capable of shaping metabolic, transcriptional and epigenetic processes within the TME in a therapeutically meaningful way.
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.
(1) Background: Interventional endoscopic procedures are growing more popular, requiring innovative instruments and novel techniques. Three-dimensional printing has demonstrated great potential for the rapid development of prototypes that can be used for the early assessment of various concepts. In this work, we present the development of a flexible endoscopic instrument and explore its potential benefits. (2) Methods: The properties of the instrument, such as its maneuverability, flexibility, and bending force, were evaluated in a series of bench tests. Additionally, the effectiveness of the instrument was evaluated in an ex vivo porcine model by medical experts, who graded its properties and performance. Furthermore, the time necessary to complete various interventional endoscopic tasks was recorded. (3) Results: The instrument achieved bending angles of ±216° while achieving a bending force of 7.85 (±0.53) Newtons. The time needed to reach the operating region was 120 s median, while it took 70 s median to insert an object in a cavity. Furthermore, it took 220 s median to insert the instrument and remove an object from the cavity. (4) Conclusions: This study presents the development of a flexible endoscopic instrument using three-dimensional printing technology and its evaluation. The instrument demonstrated high bending angles and forces, and superior properties compared to the current state of the art. Furthermore, it was able to complete various interventional endoscopic tasks in minimal time, thus potentially leading to the improved safety and effectiveness of interventional endoscopic procedures in the future.
We assume that a specific health constraint, e.g., a certain aspect of bodily function or quality of life that is measured by a variable X, is absent (or irrelevant) in a healthy reference population (Ref0), and it is materially present and precisely measured in a diseased reference population (Ref1). We further assume that some amount of this constraint of interest is suspected to be present in a population under study (SP). In order to quantify this issue, we propose the introduction of an intuitive measure, the population comparison index (PCI), that relates the mean value of X in population SP to the mean values of X in populations Ref0 and Ref1. This measure is defined as PCI[X] = (mean[X|SP] − mean[X|Ref0])/(mean[X|Ref1] − mean[X|Ref0]) × 100[%], where mean[X|.] is the average value of X in the respective group of individuals. For interpretation, PCI[X] ≈ 0 indicates that the values of X in the population SP are similar to those in population Ref0, and hence, the impairment measured by X is not materially present in the individuals in population SP. On the other hand, PCI[X] ≈ 100 means that the individuals in SP exhibit values of X comparable to those occurring in Ref1, i.e., the constraint of interest is equally present in populations SP and Ref1. A value of 0 < PCI[X] < 100 indicates that a certain percentage of the constraint is present in SP, and it is more than in Ref0 but less than in Ref1. A value of PCI[X] > 100 means that population SP is even more affected by the constraint than population Ref1.
Tuberculosis (TB) is one of the leading causes of death by an infectious disease. It remains a major health burden worldwide, in part due to misdiagnosis. Therefore, improved diagnostic tests allowing the faster and more reliable diagnosis of patients with active TB are urgently needed. This prospective study examined the performance of the new molecular whole-blood test T-Track\(^®\) TB, which relies on the combined evaluation of IFNG and CXCL10 mRNA levels, and compared it to that of the QuantiFERON\(^®\)-TB Gold Plus (QFT-Plus) enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy and agreement analyses were conducted on the whole blood of 181 active TB patients and 163 non-TB controls. T-Track\(^®\) TB presented sensitivity of 94.9% and specificity of 93.8% for the detection of active TB vs. non-TB controls. In comparison, the QFT-Plus ELISA showed sensitivity of 84.3%. The sensitivity of T-Track\(^®\) TB was significantly higher (p < 0.001) than that of QFT-Plus. The overall agreement of T-Track\(^®\) TB with QFT-Plus to diagnose active TB was 87.9%. Out of 21 samples with discordant results, 19 were correctly classified by T-Track\(^®\) TB while misclassified by QFT-Plus (T-Track\(^®\) TB-positive/QFT-Plus-negative), and two samples were misclassified by T-Track\(^®\) TB while correctly classified by QFT-Plus (T-Track\(^®\) TB-negative/QFT-Plus-positive). Our results demonstrate the excellent performance of the T-Track\(^®\) TB molecular assay and its suitability to accurately detect TB infection and discriminate active TB patients from non-infected controls.
For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but were only reported for a minority of resistant patients. The proteasome is a large and complex machinery. Here, we focus on the AAA ATPases of the 19S proteasome regulator (PSMC1-6) and their implication in PI resistance. As an example of cancer evolution and the acquisition of resistance, we conducted an in-depth analysis of an index patient by applying FISH, WES, and immunoglobulin-rearrangement sequencing in serial samples, starting from MGUS to newly diagnosed Multiple Myeloma to a PI-resistant relapse. The WES analysis uncovered an acquired PSMC2 Y429S mutation at the relapse after intensive bortezomib-containing therapy, which was functionally confirmed to mediate PI resistance. A meta-analysis comprising 1499 newly diagnosed and 447 progressed patients revealed a total of 36 SNVs over all six PSMC genes that were structurally accumulated in regulatory sites for activity such as the ADP/ATP binding pocket. Other alterations impact the interaction between different PSMC subunits or the intrinsic conformation of an individual subunit, consequently affecting the folding and function of the complex. Interestingly, several mutations were clustered in the central channel of the ATPase ring, where the unfolded substrates enter the 20S core. Our results indicate that PSMC SNVs play a role in PI resistance in MM.
Purpose
Growing evidence implies that transition to parenthood triggers symptoms of mental burden not only in women but likewise in men, especially in high-risk pregnancies. This is the first study that examined and compared the prevalence rates of depression, anxiety, and somatic symptom burden of expectant fathers who face different risk situations during pregnancy.
Methods
Prevalence rates of paternal depression (Edinburgh postnatal depression scale), anxiety (generalized anxiety disorder seven), and somatic symptom burden (somatic symptom scale eight) were examined in two risk samples and one control group in the third trimester of their partners’ pregnancy: risk sample I (n = 41) consist of expectant fathers whose partners were prenatally hospitalized due to medical complications; risk sample II (n = 52) are fathers whose partners were prenatally mentally distressed; and control group (n = 70) are those non-risk pregnancies.
Results
On a purely descriptive level, the data display a trend of higher symptom burden of depression, anxiety, and somatic symptoms in the two risk samples, indicating that expectant fathers, whose pregnant partners were hospitalized or suffered prenatal depression, were more prenatally distressed. Exploratory testing of group differences revealed an almost three times higher prevalence rate of anxiety in fathers whose partner was hospitalized (12.2%) compared to those non-risks (4.3%).
Conclusion
Results underline the need for screening implementations for paternal prenatal psychological distress, as well as specific prevention and treatment programs, especially for fathers in risk situations, such as their pregnant partners’ prenatal hospitalization.
The study was registered with the German clinical trials register (DRKS00020131) on 2019/12/09.
Purpose
Oncologists are at an increased risk of developing burnout, leading to negative consequences in patient care and in professional satisfaction and quality of life. This study was designed to investigate exhaustion and disengagement among German oncologists and assess the prevalence of burnout among oncologists within different professional settings. Furthermore, we wanted to examine possible relations between sociodemographic factors, the oncological setting, professional experience and different aspects of burnout.
Methods
In a cross-sectional study design, an Internet-based survey was conducted with 121 oncologists between April and July 2020 using the Oldenburg Burnout Inventory, which contains items on exhaustion, disengagement, and burnout. Furthermore, sociodemographic data of the participants were assessed. The participants were members of the Working Group Medical Oncology (Arbeitsgemeinschaft Internistische Onkologie) within the German Cancer Society.
Results
The survey showed a burnout prevalence of 43.8%, which correlated with age and professional experience; that is, the prevalence is particularly high among younger oncologists. Exhaustion is closely related to employment status; that is, it was significantly higher among employed oncologists. There were remarkably low levels of disengagement among oncologists, highlighting the own demand to fulfil job requirements despite imminent or actual overburdening in daily work.
Conclusion
More support is necessary to mitigate the professional stressors in the healthcare system. To ensure quality medical care, employees should be offered preventive mental health services early in their careers.
Objective
Blindness is a feared complication of giant cell arteritis (GCA). However, the spectrum of pathologic orbital imaging findings on magnetic resonance imaging (MRI) in GCA is not well understood. In this study, we assess inflammatory changes of intraorbital structures on black blood MRI (BB-MRI) in patients with GCA compared to age-matched controls.
Methods
In this multicenter case-control study, 106 subjects underwent BB-MRI. Fifty-six patients with clinically or histologically diagnosed GCA and 50 age-matched controls without clinical or laboratory evidence of vasculitis were included. All individuals were imaged on a 3-T MR scanner with a post-contrast compressed-sensing (CS) T1-weighted sampling perfection with application-optimized contrasts using different flip angle evolution (SPACE) BB-MRI sequence. Imaging results were correlated with available clinical symptoms.
Results
Eighteen of 56 GCA patients (32%) showed inflammatory changes of at least one of the intraorbital structures. The most common finding was enhancement of at least one of the optic nerve sheaths (N = 13, 72%). Vessel wall enhancement of the ophthalmic artery was unilateral in 8 and bilateral in 3 patients. Enhancement of the optic nerve was observed in one patient. There was no significant correlation between imaging features of inflammation and clinically reported orbital symptoms (p = 0.10). None of the age-matched control patients showed any inflammatory changes of intraorbital structures.
Conclusions
BB-MRI revealed inflammatory findings in the orbits in up to 32% of patients with GCA. Optic nerve sheath enhancement was the most common intraorbital inflammatory change on BB-MRI. MRI findings were independent of clinically reported orbital symptoms.
Key Points
• Up to 32% of GCA patients shows signs of inflammation of intraorbital structures on BB-MRI.
• Enhancement of the optic nerve sheath is the most common intraorbital finding in GCA patients on BB-MRI.
• Features of inflammation of intraorbital structures are independent of clinically reported symptoms.
While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.
Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson’s disease (PD). One trigger of the immune system in PD is aggregation of the pre-synaptic protein, α-synuclein (αSyn). Understanding the mechanism of propagation of αSyn aggregates is essential to developing disease-modifying therapeutics. Using a brain-first mouse model of PD, we demonstrate αSyn trafficking from the brain to the ileum of male mice. Immunohistochemistry revealed that the ileal αSyn aggregations are contained within CD11c+ cells. Using single-cell RNA sequencing, we demonstrate that ileal CD11c\(^+\) cells are microglia-like and the same subtype of cells is activated in the brain and ileum of PD mice. Moreover, by utilizing mice expressing the photo-convertible protein, Dendra2, we show that CD11c\(^+\) cells traffic from the brain to the ileum. Together these data provide a mechanism of αSyn trafficking between the brain and gut.
Pathogen-specific innate immune response patterns are distinctly affected by genetic diversity
(2023)
Innate immune responses vary by pathogen and host genetics. We analyze quantitative trait loci (eQTLs) and transcriptomes of monocytes from 215 individuals stimulated by fungal, Gram-negative or Gram-positive bacterial pathogens. We identify conserved monocyte responses to bacterial pathogens and a distinct antifungal response. These include 745 response eQTLs (reQTLs) and corresponding genes with pathogen-specific effects, which we find first in samples of male donors and subsequently confirm for selected reQTLs in females. reQTLs affect predominantly upregulated genes that regulate immune response via e.g., NOD-like, C-type lectin, Toll-like and complement receptor-signaling pathways. Hence, reQTLs provide a functional explanation for individual differences in innate response patterns. Our identified reQTLs are also associated with cancer, autoimmunity, inflammatory and infectious diseases as shown by external genome-wide association studies. Thus, reQTLs help to explain interindividual variation in immune response to infection and provide candidate genes for variants associated with a range of diseases.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The best method to prevent CRC is with a colonoscopy. During this procedure, the gastroenterologist searches for polyps. However, there is a potential risk of polyps being missed by the gastroenterologist. Automated detection of polyps helps to assist the gastroenterologist during a colonoscopy. There are already publications examining the problem of polyp detection in the literature. Nevertheless, most of these systems are only used in the research context and are not implemented for clinical application. Therefore, we introduce the first fully open-source automated polyp-detection system scoring best on current benchmark data and implementing it ready for clinical application. To create the polyp-detection system (ENDOMIND-Advanced), we combined our own collected data from different hospitals and practices in Germany with open-source datasets to create a dataset with over 500,000 annotated images. ENDOMIND-Advanced leverages a post-processing technique based on video detection to work in real-time with a stream of images. It is integrated into a prototype ready for application in clinical interventions. We achieve better performance compared to the best system in the literature and score a F1-score of 90.24% on the open-source CVC-VideoClinicDB benchmark.
Long-term sequelae in hospitalized Coronavirus Disease 2019 (COVID-19) patients may result in limited quality of life. The current study aimed to determine health-related quality of life (HRQoL) after COVID-19 hospitalization in non-intensive care unit (ICU) and ICU patients. This is a single-center study at the University Hospital of Wuerzburg, Germany. Patients eligible were hospitalized with COVID-19 between March 2020 and December 2020. Patients were interviewed 3 and 12 months after hospital discharge. Questionnaires included the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), patient health questionnaire-9 (PHQ-9), the generalized anxiety disorder 7 scale (GAD-7), FACIT fatigue scale, perceived stress scale (PSS-10) and posttraumatic symptom scale 10 (PTSS-10). 85 patients were included in the study. The EQ5D-5L-Index significantly differed between non-ICU (0.78 ± 0.33 and 0.84 ± 0.23) and ICU (0.71 ± 0.27; 0.74 ± 0.2) patients after 3- and 12-months. Of non-ICU 87% and 80% of ICU survivors lived at home without support after 12 months. One-third of ICU and half of the non-ICU patients returned to work. A higher percentage of ICU patients was limited in their activities of daily living compared to non-ICU patients. Depression and fatigue were present in one fifth of the ICU patients. Stress levels remained high with only 24% of non-ICU and 3% of ICU patients (p = 0.0186) having low perceived stress. Posttraumatic symptoms were present in 5% of non-ICU and 10% of ICU patients. HRQoL is limited in COVID-19 ICU patients 3- and 12-months post COVID-19 hospitalization, with significantly less improvement at 12-months compared to non-ICU patients. Mental disorders were common highlighting the complexity of post-COVID-19 symptoms as well as the necessity to educate patients and primary care providers about monitoring mental well-being post COVID-19.
Butyrophilin (BTN)–3A and BTN2A1 molecules control the activation of human Vγ9Vδ2 T cells during T cell receptor (TCR)-mediated sensing of phosphoantigens (PAg) derived from microbes and tumors. However, the molecular rules governing PAg sensing remain largely unknown. Here, we establish three mechanistic principles of PAg-mediated γδ T cell activation. First, in humans, following PAg binding to the intracellular BTN3A1-B30.2 domain, Vγ9Vδ2 TCR triggering involves the extracellular V-domain of BTN3A2/BTN3A3. Moreover, the localization of both protein domains on different chains of the BTN3A homo-or heteromers is essential for efficient PAg-mediated activation. Second, the formation of BTN3A homo-or heteromers, which differ in intracellular trafficking and conformation, is controlled by molecular interactions between the juxtamembrane regions of the BTN3A chains. Finally, the ability of PAg not simply to bind BTN3A-B30.2, but to promote its subsequent interaction with the BTN2A1-B30.2 domain, is essential for T-cell activation. Defining these determinants of cooperation and the division of labor in BTN proteins improves our understanding of PAg sensing and elucidates a mode of action that may apply to other BTN family members.
Introduction: National and international guidelines recommend early integration of evidence-based multimodal interventions and programs, especially with a focus on relaxation techniques and other Mind–Body-based methods to maintain the quality of life of oncology patients, improve treatment tolerability, and promote healthy lifestyle behaviors. Consequently, we aim to understand what drives patients and how they navigate integrative medicine to best advise them. This study aimed to detect possible topics of particular interest to patients and identify the patient groups that could benefit most from further programs. Furthermore, we aimed to investigate if patients are open-minded toward integrative oncology concepts and learn about their motivational level to maintain or change behavior.
Methods: Between August 2019 and October 2020 we surveyed patients undergoing oncological therapy in a university oncological outpatient center using a custom-developed questionnaire based on established Mind–Body Medicine concepts.
Results: We included 294 patients with various cancers. More than half reported problems sleeping through (61%) and 42% felt stressed frequently, invariably rating this as detrimental to their health. Moreover, a slight majority (52%) felt physically limited due to their disease and only 30% performed defined exercise programs. Women were significantly more likely to feel stressed and reported with alarming frequency that they often feel “everything was up to them.” The 40–65-year-olds reported significantly less restful sleep, more stress and were more dissatisfied with their situation. However, this group already used natural remedies most frequently and was most often motivated to use relaxation techniques in the next 6 months. The lower the perceived individual energy level (EL), the less frequently patients did sport, the more frequently they felt their disease impaired their activity, mostly feeling stressed and tense. We also found significant associations between negative emotions/thoughts and the variables “sleep,” “use of relaxation techniques,” “personal stress perception,” and “successful lifestyle modification.”
Conclusion: Mind–Body programs that focus on patient’s individual resources, with tools to explore impairing patterns of self-perception and cognitive biases, can be a valuable resource for oncology patients and should therefore be part of an integrative medical treatment concept.